Larotrectinib has been given a positive opinion by NICE, following the submission of a revised price after it was previously rejected.
List view / Grid view
Cancer Drug Fund (CDF)
Filter the results
The NICE committee has made palbociclib with fulvestrant available on the Cancer Drug Fund for patients with hormone receptor-positive, HER2-negative, advanced breast cancer.